Register for free to
view the full innovation profile.
This novel vaccine is comprised of inactivated whole tumor cells that lack the CD47 protein, making them more susceptible to immune cells in the body
About
This invention uses human genome editing to convert cancer cells into therapeutic cancer vaccines. The introduction of these genome edited tumor cells into patients will trigger the body’s immune system to recognize and attack cancer cells, leading a significant reduction of cancerous cells. This new cancer therapy could potentially save millions of lives.
Key Benefits
It does not require the delivery of antibodies or DNA plasmids to tumors, which is less efficient than this technology usually hard to achieve. Genome deletion of CD47 removes the protection of cancer cells from being recognized by macrophages; thus, it elicits much higher level of immunogenicity after administration compared to the use of dead unmodified cancer cells. It uses patients' own cells, eliminating the problem of immune rejection. It is efficient against metastatic cancer cells.